5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer

Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma

(2021) Dan Liu et al.   Frontiers in Immunology

RNA Modification of N6-Methyladenosine Predicts Immune Phenotypes and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma

(2021) Huihuang Li et al.   Frontiers in Oncology

Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer

(2021) Dongqiang Zeng et al.   Journal for ImmunoTherapy of Cancer

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines

(2020) J. Alfred Witjes et al.   EUROPEAN UROLOGY

Deep Learning Predicts Molecular Subtype of Muscle-invasive Bladder Cancer from Conventional Histopathological Slides

(2020) Ann-Christin Woerl et al.   EUROPEAN UROLOGY

Identification of cross-talk between m6A and 5mC regulators associated with onco-immunogenic features and prognosis across 33 cancer types

(2020) Yu-Tong Chen et al.   Journal of Hematology & Oncology

m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer

(2020) Bo Zhang et al.   Molecular Cancer

Mast cell‐based molecular subtypes and signature associated with clinical outcome in early‐stage lung adenocarcinoma

(2020) Xuanwen Bao et al.   Molecular Oncology

TIMER2.0 for analysis of tumor-infiltrating immune cells

(2020) Taiwen Li et al.   NUCLEIC ACIDS RESEARCH

Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient

(2020) Hye Won Lee et al.   Genome Medicine

Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy

(2020) Markus Eckstein et al.   Journal for ImmunoTherapy of Cancer

Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer

(2020) Andrea Necchi et al.   EUROPEAN UROLOGY

DNA Methylation as a Therapeutic Target for Bladder Cancer

(2020) Sandra P. Nunes et al.   Cells

Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer

(2020) Xu Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting the epigenetic regulation of antitumour immunity

(2020) Simon J. Hogg et al.   NATURE REVIEWS DRUG DISCOVERY

Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma

(2020) Zhaohui Chen et al.   Nature Communications

Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures

(2019) Dongqiang Zeng et al.   Cancer Immunology Research

Molecular Characterization of Neuroendocrine-like Bladder Cancer

(2019) José Batista da Costa et al.   CLINICAL CANCER RESEARCH

Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data

(2019) Francesca Finotello et al.   Genome Medicine

Management of metastatic bladder cancer

(2019) Rosa Nadal et al.   CANCER TREATMENT REVIEWS

Metascape provides a biologist-oriented resource for the analysis of systems-level datasets

(2019) Yingyao Zhou et al.   Nature Communications

A Consensus Molecular Classification of Muscle-invasive Bladder Cancer

(2019) Aurélie Kamoun et al.   EUROPEAN UROLOGY

Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation

(2018) Tathiane M. Malta et al.   CELL

Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas

(2018) Qianxing Mo et al.   JNCI-Journal of the National Cancer Institute

Readers of DNA methylation, the MBD family as potential therapeutic targets

(2018) Gordon D. Ginder et al.   PHARMACOLOGY & THERAPEUTICS

Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas

(2018) Qianxing Mo et al.   JNCI-Journal of the National Cancer Institute

PCA-based GRS analysis enhances the effectiveness for genetic correlation detection

(2018) Yan Zhao et al.   BRIEFINGS IN BIOINFORMATICS

TIP: A web server for resolving tumor immunophenotype profiling

(2018) Liwen Xu et al.   CANCER RESEARCH

Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy

(2018) Subhankar Biswas et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants

(2018) Joshua I. Warrick et al.   EUROPEAN UROLOGY

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

(2018) Peng Jiang et al.   NATURE MEDICINE

Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

(2018) Noam Auslander et al.   NATURE MEDICINE

Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy

(2018) Jose Batista da Costa et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

Intra-tumor heterogeneity from a cancer stem cell perspective

(2017) Pramudita R. Prasetyanti et al.   Molecular Cancer

TET-mediated active DNA demethylation: mechanism, function and beyond

(2017) Xiaoji Wu et al.   NATURE REVIEWS GENETICS

Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade

(2017) Pornpimol Charoentong et al.   Cell Reports

Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types

(2017) Je-Keun Rhee et al.   Cancer Immunology Research

FOXA1, GATA3 and PPARɣ Cooperate to Drive Luminal Subtype in Bladder Cancer: A Molecular Analysis of Established Human Cell Lines

(2016) Joshua I. Warrick et al.   Scientific Reports

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

(2015) Katherine B. Chiappinelli et al.   CELL

Function and information content of DNA methylation

(2015) Dirk Schübeler   NATURE

Robust enumeration of cell subsets from tissue expression profiles

(2015) Aaron M Newman et al.   NATURE METHODS

Systematic pan-cancer analysis of tumour purity

(2015) Dvir Aran et al.   Nature Communications

Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy

(2014) Woonyoung Choi et al.   CANCER CELL

Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin

(2014) Katherine A. Hoadley et al.   CELL

Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology

(2014) J. S. Damrauer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype

(2014) S. Rebouissou et al.   Science Translational Medicine

GSVA: gene set variation analysis for microarray and RNA-Seq data

(2013) Sonja Hänzelmann et al.   BMC BIOINFORMATICS

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer

(2013) Gopa Iyer et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

(2013) H Yang et al.   LEUKEMIA

The causes and consequences of genetic heterogeneity in cancer evolution

(2013) Rebecca A. Burrell et al.   NATURE

DNA methylation-based biomarkers in bladder cancer

(2013) Raju Kandimalla et al.   Nature Reviews Urology

A Molecular Taxonomy for Urothelial Carcinoma

(2012) G. Sjodahl et al.   CLINICAL CANCER RESEARCH

A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response

(2012) Laurens Kruidenier et al.   NATURE

Molecular signatures database (MSigDB) 3.0

(2011) A. Liberzon et al.   BIOINFORMATICS

Increased methylation variation in epigenetic domains across cancer types

(2011) Kasper Daniel Hansen et al.   NATURE GENETICS

ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking

(2010) Matthew D. Wilkerson et al.   BIOINFORMATICS

What is principal component analysis?

(2008) Markus Ringnér   NATURE BIOTECHNOLOGY